Designates portions of this document have been omitted pursuant to a request for confidential treatment filed separately with the Commission] DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • August 15th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on May 9, 2016 (the “Effective Date”), by and between Watson Laboratories, Inc., a Nevada corporation (“Watson”), on the one hand, and Adamis Pharmaceuticals Corporation, a company incorporated under the laws of Delaware (“Adamis”), on the other hand. Watson and Adamis shall each sometimes be referred to herein as a “Party” and collectively as the “Parties.”
LOAN AMENDMENT, FORBEARANCE AND ASSUMPTION AGREEMENTLoan Amendment, Forbearance and Assumption Agreement • August 15th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Arkansas
THIS LOAN AMENDMENT, FORBEARANCE AND ASSUMPTION AGREEMENT (this “Agreement”) is made and entered into as of April _____, 2016 (the “Agreement Date”), by and among 4 HIMS, LLC, an Arkansas limited liability company (“4 HIMS”), Tribute Labs, LLC, a Nevada limited liability company (“Tribute”), US Compounding, Inc., an Arkansas corporation (“USC”) (4 HIMS, Tribute and USC are collectively hereinafter referred to as the “Initial Loan Parties”); EDDIE GLOVER, an individual, and WILLIAM L. SPARKS, an individual; and KRISTEN RIDDLE, an individual (collectively, the “Individual Guarantors”); Adamis Pharmaceuticals Corporation, a Delaware corporation (“Adamis”); and Bear State Bank, INC., a national banking association (“Bank”).
